Abstracts

THE LEVI SYNDROME: CHARACTERISTICS OF EARLY HIV INFECTION WITH CABOTEGRAVIR FOR PrEP

Background: HPTN 083 and HPTN 084 demonstrated that long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) was superior to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV prevention. Twenty HIV infections were detected in the cabotegravir (CAB) arm during the blinded phase of the trials (5 baseline infections; 15 incident infections; 16 in HPTN 083 over…

MOLECULAR HIV CLUSTERING OF INDIVIDUALS WITH MPOX/HIV COMORBIDITY

Background: HIV cluster detection and response (CDR) is a key part of the federal Ending the HIV Epidemic initiative in the United States. HIV molecular clusters are thought to preferentially include individuals that are at highest risk of HIV transmission and the most stringent clusters are assumed to indicate recent and rapid transmission. The global…

CABOTEGRAVIR PHARMACOLOGY IN THE BACKGROUND OF DELAYED INJECTIONS IN HPTN 084

Background: HPTN 084, a Phase 3 randomized, placebo-controlled trial, demonstrated the superiority of long-acting injectable cabotegravir (CAB) compared to daily oral TDF/FTC for HIV prevention in individuals assigned female at birth. Injections were provided at 8-week intervals after the first two injections were separated by 4 weeks. While there were protocol-specified visit windows for injections,…

CABOTEGRAVIR FOR HIV PrEP IN US BLACK MEN AND TRANSGENDER WOMEN WHO HAVE SEX WITH MEN

Background: HIV infections are disproportionally higher among Black cisgender men and transgender women who have sex with men (MSM and TGW) compared with other racial/ethnic groups in the US. Long-acting injectable cabotegravir (CAB-LA) for HIV pre-exposure prophylaxis (PrEP) was shown to be safe and effective across populations globally. We evaluated HIV incidence and prevention efficacy…

HIV INCIDENCE DIFFERENCES MEASURED BY SERIAL CROSS-SECTIONAL TESTING: HPTN 071

Background: HPTN 071 (PopART) was a community-randomized trial conducted in Zambia and South Africa (2013-2018); 21 communities were randomized into three arms in 7 triplets matched on baseline HIV prevalence and location (Arm A: combination prevention intervention with universal antiretroviral treatment [ART]; Arm B: combination prevention intervention with ART provided according to local guidelines; Arm…

INCIDENCE OF CANCER AMONG MEDICAID BENEFICIARIES WITH AND WITHOUT HIV: 2001-2015

Background: Life expectancy among people living with HIV (PLH) is approaching the general population, and chronic conditions associated with aging—including cancer—are increasingly relevant. Among PLH, incidence of AIDS-defining cancers (ADCs) has decreased, and the cancer burden has shifted toward non-AIDS-defining cancers (NADCs). Medicaid provides insurance for 40% of PLH in the US and may offer…